Proteome Sciences Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3.76	4.89	5.03	7.78	5.13
Revenue Growth (YoY)	-23.14%	-2.80%	-35.37%	51.69%	7.91%
Cost of Revenue	3.84	4.22	3.38	3.01	2.17
Gross Profit	-0.08	0.67	1.65	4.77	2.96
Selling, General & Admin	1.66	2.19	2.78	2.64	2.34
Operating Expenses	2.59	3.02	3.27	3.04	2.55
Operating Income	-2.67	-2.35	-1.62	1.73	0.41
Interest Expense	-0.93	-0.9	-0.8	-0.47	-0.29
Pretax Income	-3.59	-3.25	-2.42	1.26	0.12
Income Tax Expense	-0.53	0.16	0.03	-0.07	0.05
Net Income	-3.06	-3.41	-2.44	1.33	0.07
Net Income to Common	-3.06	-3.41	-2.44	1.33	0.07
Net Income Growth	-	-	-	1740.28%	-75.59%
Shares Outstanding (Basic)	295	295	295	295	295
Shares Outstanding (Diluted)	305	307	295	309	302
Shares Change (YoY)	-0.81%	4.11%	-4.48%	2.38%	2.26%
EPS (Basic)	-0.01	-0.01	-0.01	0.00	0.00
EPS (Diluted)	-0.01	-0.01	-0.01	0.00	0.00
EPS Growth	-	-	-	2060.30%	-80.08%
Free Cash Flow	-0.14	-1.05	-0.72	1.82	0.59
Free Cash Flow Per Share	-	-0.00	-0.00	0.01	0.00
Gross Margin	-2.16%	13.71%	32.76%	61.27%	57.71%
Operating Margin	-70.98%	-48.15%	-32.24%	22.21%	8.03%
Profit Margin	-81.50%	-69.69%	-48.59%	17.03%	1.40%
Free Cash Flow Margin	-3.81%	-21.49%	-14.28%	23.41%	11.48%
EBITDA	-2.49	-2.2	-1.5	1.83	0.45
EBITDA Margin	-66.19%	-45.08%	-29.79%	23.57%	8.81%
D&A For EBITDA	0.18	0.15	0.12	0.11	0.04
EBIT	-2.67	-2.35	-1.62	1.73	0.41
EBIT Margin	-70.98%	-48.15%	-32.24%	22.21%	8.03%
Effective Tax Rate	-	-	-	-	38.98%
Revenue as Reported	3.76	4.89	5.03	7.78	5.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.